Please login to the form below

Not currently logged in
Email:
Password:

Valeant acquires GSK's Zovirax

Valeant Pharmaceuticals' Biovail Laboratories has signed a deal under which it will acquire all US and Canadian rights to certain formulations of GSK's Zovirax

Valeant Pharmaceuticals' Biovail Laboratories has signed a deal under which it will acquire all US and Canadian rights to non-ophthalmic topical formulations of GlaxoSmithKline's (GSK) herpes drug Zovirax (acyclovir) for $300m.

Biovail was already the exclusive distributor of the product in the US, where the deal will allow the company to keep more of the profits from the drug. Biovail did not previously have rights to the drug in Canada.

"The current distribution agreement between GSK and Biovail was problematic for both companies and this new arrangement should solve this issue for both organisations,” Valeant CEO J Michael Pearson said in a statement.  "We believe that our sales and marketing organisations in the United States and Canada have the ability to revitalise and grow the brand."

Zovirax ointment and cream are indicated for genital herpes and cold sores. Biovail paid $133m for the marketing rights to the topical formulations of Zovirax in a ten-year deal signed between the companies in 2001. In late 2002, Biovail announced that it had extended its existing 10-year agreement with GSK for the marketing rights to 20 years for an additional payment of $40m.

4th February 2011

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Flu
Influenza – the risk to vulnerable populations
Why we can't get complacent about flu vaccination...
dementia
Alzheimer’s Research UK highlights socio-economic inequalities in dementia risk
The charity aims to improve the number of women participating in dementia research and grow awareness of dementia risk factors...
Data security
Concerns about data security are building a strong case for clinical mobility in EMEA
Electronic medical records have transformed the storage of sensitive information but how can the healthcare sector continue to protect patient and staff data?...